Immediate Impact
2 from Science/Nature 55 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Bispecific antibodies: advancing precision oncology
2024 Standout
Works of Pankit Vachhani being referenced
Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Pankit Vachhani | 350 | 98 | 252 | 225 | 75 | 693 | |
| Joost M. Meijer | 196 | 257 | 157 | 95 | 45 | 843 | |
| Mônica Glória Neumann Spínelli | 311 | 91 | 202 | 69 | 57 | 706 | |
| Mirco Friedrich | 67 | 66 | 251 | 167 | 37 | 712 | |
| Laura Pardo | 357 | 78 | 160 | 220 | 45 | 677 | |
| Ibtissam Youlyouz‐Marfak | 141 | 58 | 132 | 157 | 37 | 647 | |
| Deniz Peker | 241 | 132 | 118 | 165 | 55 | 749 | |
| Luz Muñoz | 302 | 88 | 136 | 188 | 36 | 784 | |
| Mariusz Wysocki | 229 | 98 | 180 | 204 | 146 | 839 | |
| Tahsin Yakut | 75 | 82 | 310 | 86 | 81 | 748 | |
| Annie Im | 393 | 135 | 239 | 292 | 63 | 822 |
All Works
Login with ORCID to disown or claim papers
Loading papers...